Commenting on the 2019 results and 2020 guidance, Herman Verrelst, Chief Executive Officer of Biocartis, said: “The financials that we disclose today show a continued healthy growth in revenues and a cash position that allows us to further execute on our plans for the coming years. More importantly, we today also announce a strong outlook for 2020 in which we expect to see an encouraging growth of our cartridge volumes. Our 2020 outlook is driven by a strong Q4 2019, our sizeable installed base, our new US go-to-market strategy announced in September 2019, a good outlook for Europe and RoW3 as well as the menu expansion realized in 2019 through the CE-marking of our Idylla™ MSI Test and launch of our Idylla™ ctEGFR Mutation Assay. I am also excited about the new and increasing research use of our Idylla™ assays in exploring pan-tumor settings – pointing to a broader applicability of the test menu on the Idylla™ platform. We expect more publications on this topic over the course of 2020. In addition, towards end 2020 we expect to see important new assay launches, by ourselves and our partners, and we expect our first oncology US FDA filing. All of this will fuel growth for 2021 and the years to come, also supported by the progress we are making in our commercial plans for China and Japan, both sizable untapped markets for Biocartis. 2019 was an eventful year, but we finished it in a position of strength. I confidently look forward to 2020 and beyond.”